Approval · Notice of Compliance 38301 · 2026
PROLEUKIN: Notice of Compliance 38301
Issued September 16, 2026
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 38301
- Date
- September 16, 2026
- Company
- Iovance Biotherapeutics Manufacturing LlcPhiladelphia, Pennsylvania, United States
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Update to the Product Monograph. Labelling updates
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| PROLEUKIN | 02130181 | Marketed |
Medicinal ingredients
- ALDESLEUKIN 22,000,000 UNIT per VIAL